Amgen (MEX:AMG N) Cyclically Adjusted FCF per Share: MXN328.58 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AMG N Amgen Inc MEX:AMG N
86 GF Score
Price MXN6,349.00
GF Value MXN6,131.29
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Amgen Cyclically Adjusted FCF per Share?

Amgen MEX:AMG N 86 Cyclically Adjusted FCF per Share is MXN328.58 as of Mar. 2026. GuruFocus rates MEX:AMG N with a GF Score™ of 86/100 and a GF Value™ of MXN6,131.29 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Amgen's adjusted free cash flow per share for the three months ended in Mar. 2026 was MXN48.960. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN328.58 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Amgen's average Cyclically Adjusted FCF Growth Rate was 2.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 8.00% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Amgen was 25.30% per year. The lowest was 4.70% per year. And the median was 15.20% per year.

As of today (2026-07-18), Amgen's current stock price is MXN6349.00. Amgen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was MXN328.58. Amgen's Cyclically Adjusted Price-to-FCF of today is 19.32.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 24.24. The lowest was 13.20. And the median was 18.59.


Amgen  (MEX:AMG N) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Amgen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=6349.00/328.58
=19.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amgen was 24.24. The lowest was 13.20. And the median was 18.59.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Amgen Cyclically Adjusted FCF per Share Related Terms


Amgen Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Amgen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Cyclically Adjusted FCF per Share Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 292.71 304.88 281.37 360.94 326.21

Amgen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 367.78 332.83 334.95 326.21 328.58

MEX:AMG N vs GILD, PFE, BMY: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Amgen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Amgen's Cyclically Adjusted Price-to-FCF falls into.


MEX:AMG N
86GF Score
Amgen Inc MEX:AMG N
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amgen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=48.96/330.2130*330.2130
=48.960

Current CPI (Mar. 2026) = 330.2130.

Amgen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 58.465 241.018 80.101
201609 66.609 241.428 91.104
201612 79.828 241.432 109.183
201703 56.335 243.801 76.302
201706 52.440 244.955 70.692
201709 81.604 246.819 109.176
201712 77.341 246.524 103.596
201803 65.720 249.554 86.962
201806 57.013 251.989 74.711
201809 89.404 252.439 116.949
201812 90.946 251.233 119.537
201903 53.577 254.202 69.597
201906 39.992 256.143 51.557
201909 105.170 256.759 135.257
201912 73.481 256.974 94.423
202003 78.634 258.115 100.598
202006 104.649 257.797 134.045
202009 121.257 260.280 153.837
202012 67.442 260.474 85.499
202103 68.184 264.877 85.003
202106 60.340 271.696 73.336
202109 78.496 274.310 94.493
202112 91.695 278.802 108.604
202203 71.333 287.504 81.930
202206 63.089 296.311 70.307
202209 105.361 296.808 117.219
202212 83.673 296.797 93.094
202303 24.123 301.836 26.391
202306 122.529 305.109 132.611
202309 81.331 307.789 87.256
202312 9.118 306.746 9.816
202403 14.212 312.332 15.026
202406 75.211 314.175 79.050
202409 120.394 315.301 126.088
202412 169.621 315.605 177.472
202503 37.059 319.799 38.266
202506 66.511 322.561 68.089
202509 143.775 324.800 146.171
202512 31.925 324.054 32.532
202603 48.960 330.213 48.960

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN328.58 mean?
Amgen (MEX:AMG N) has a Cyclically Adjusted FCF per Share of MXN328.58 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Amgen and its competitors.
Is Amgen's Cyclically Adjusted FCF per Share too high?
Amgen's current Cyclically Adjusted FCF per Share is MXN328.58. Overall, Amgen has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Cyclically Adjusted FCF per Share compare to GILD and PFE?
Amgen's Cyclically Adjusted FCF per Share of MXN328.58 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Amgen and its competitors. Amgen's current Cyclically Adjusted FCF per Share is MXN328.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (MEX:AMG N) is currently considered Fairly Valued. The stock's GF Value™ is MXN6,131.29, compared to a current price of MXN6,349.00 — trading 3.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN328.58. Amgen's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Amgen (MEX:AMG N), the current Cyclically Adjusted FCF per Share is MXN328.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (MEX:AMG N) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of MXN6,349.00 is trading 3.6% above its estimated GF Value™ of MXN6,131.29. GuruFocus considers Amgen to be Fairly Valued.

Key valuation signals for MEX:AMG N:

  • Cyclically Adjusted FCF per Share: MXN328.58
  • GF Value™: MXN6,131.29 vs. price of MXN6,349.00 (3.6% above fair value)
  • GF Score™: 86/100 with 8 warning signs

No single metric tells the full story. See the MEX:AMG N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
86GF Score

Get the complete analysis for MEX:AMG N

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN6,349.00
Price
MXN6,131.29
GF Value